1. Publication
- Title: Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
- Acronym: HI-PEITHO
- Year & Journal: New England Journal of Medicine, epublished March 28, 2026
- Citation: Rosenfield K, Klok FA, Piazza G, et al; HI-PEITHO Investigators. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism. N Engl J Med. 2026. doi:10.1056/NEJMoa2516567
2. Context & Rationale
Background: For hemodynamically unstable PE, reperfusion is accepted practice; for hemodynamically stable but right-heart-strained (intermediate-risk) PE, the balance between preventing collapse and causing major bleeding remained unresolved. The original PEITHO trial showed full-dose systemic fibrinolysis reduced early hemodynamic collapse in intermediate-risk PE but caused substantially more major bleeding and intracranial hemorrhage, precluding routine adoption. Ultrasound-facilitated, catheter-directed fibrinolysis (using much lower, localized thrombolytic doses) offered a theoretical way to preserve efficacy while reducing bleeding risk.
Research Question/Hypothesis: In patients with acute intermediate-risk PE, does ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation reduce the composite of PE-related death, cardiopulmonary decompensation/collapse, or symptomatic PE recurrence within 7 days, compared with anticoagulation alone?
Why This Matters: First trial to directly compare a catheter-based strategy against systemic anticoagulation alone specifically in elevated-risk (intermediate-risk) PE, a population with substantial risk of early deterioration but for whom systemic fibrinolysis has an unfavorable risk-benefit profile.
3. Design & Methods
- Study Type: Multinational, adaptive-design, open-label, randomized trial with blinded outcome adjudication
- Setting & Centers: 59 sites, US and 8 European countries (Austria, France, Germany, Ireland, Poland, Switzerland, Netherlands, UK)
- Population:
- Inclusion: Adults 18–80y with acute intermediate-risk PE in ≥1 main or proximal lobar pulmonary artery; RV:LV ratio ≥1.0; abnormal troponin; plus ≥2 additional severity indicators
- Exclusions: Persistent hemodynamic instability
- Intervention: Ultrasound-facilitated catheter-directed fibrinolysis with alteplase (bolus 2mg/catheter, then 1mg/catheter/hour ×7h; total 9mg unilateral/18mg bilateral) plus anticoagulation
- Comparator: Anticoagulation alone
- Randomization: 1:1, 544 patients enrolled
- Blinding: Open-label treatment delivery; blinded outcome adjudication
- Statistical Power & Follow-Up: Adaptive design. Primary outcome at 7 days; safety and mortality followed to 30 days; longer-term follow-up to 12 months planned for survival/functional outcomes.
4. Key Results
Outcome | USCDT + Anticoagulation | Anticoagulation Alone | Effect Size | 95% CI / p-value | Clinical Notes |
Primary composite, 7 days (death, decompensation/collapse, or recurrence) | 4.0% | 10.3% | Not reported as single RR in accessible text | P=0.005 | Superiority achieved |
Cardiorespiratory decompensation or collapse (driver of primary result) | 3.7% | 10.3% | Not reported | — | Accounts for nearly the entire composite effect |
PE-related death | 3 patients (intervention) | 1 patient (control) | RR 3.0 | 0.3–28.5 | Point estimate favors control — the most clinically important component moved the "wrong" direction |
Symptomatic PE recurrence | 1 patient | 2 patients | Not reported | — | Small numbers |
All-cause mortality, 30 days | 1.8% | 1.1% | RR 1.7 | 0.4–6.9 | No significant difference; low event counts |
Major bleeding, 30 days | 4.1% | 3.0% | RR 1.4 | 0.6–3.4; P=0.64 | Not significantly different |
Intracranial hemorrhage | 0 | 0 | — | — | No events in either group |
Serious adverse events, 30 days | 14.8% | 16.2% | Not reported | P=0.62 | Not significantly different |
Rescue therapy required | 2.9% | 9.2% | Not reported | — | Consistent with the primary decompensation-driven effect |
5. Internal Validity Assessment
- Randomization & Allocation: Multinational, adaptive-design randomization; specific concealment mechanics not detailed in available trial text.
- Protocol Adherence & Separation: Not fully detailed; intervention (device-based catheter procedure) inherently delivers strong procedural separation from anticoagulation-alone.
- Blinding & Detection Bias: Open-label treatment delivery but blinded outcome adjudication — meaningfully reduces (though does not eliminate) detection bias, particularly important since "cardiorespiratory decompensation or collapse" (the component driving the entire primary result) could be subject to clinician judgment/reporting threshold effects.
- Missing Data & Sensitivity Analyses: Not detailed in available trial text.
- Overall Internal Validity Conclusion: Moderate — blinded adjudication is a meaningful strength, but the primary composite's effect is driven almost entirely by a softer, potentially threshold-sensitive endpoint (decompensation/collapse), while the hardest, most clinically unambiguous component (PE-related death) numerically favored the control arm (3 vs 1 events). Industry sponsorship (Boston Scientific, which also supplied the device and coordinated manuscript writing) is a relevant structural consideration for endpoint selection and reporting, as independent commentary has noted.
6. External Validity Assessment
- Population Representativeness: Age range restricted to 18–80y; specifically intermediate-risk PE with RV:LV ≥1.0, abnormal troponin, plus additional severity markers — a well-defined, moderately-high-risk PE subgroup, not unselected/all-comer PE.
- Practice Context: Requires specialized catheter-based ultrasound-facilitated thrombolysis equipment (proprietary EkoSonic device) and interventional expertise — not universally available; multinational (US/Europe) high-resource-system trial.
- Overall External Validity Conclusion: Moderate — applicable to the specific intermediate-risk PE population and health systems with catheter-based thrombolysis capability; not generalizable to unselected PE, low-risk PE, or resource-limited settings lacking this technology.
7. Strengths & Limitations
Strengths:
- First trial directly comparing a catheter-based strategy against anticoagulation alone specifically in intermediate-risk PE
- Blinded outcome adjudication
- No intracranial hemorrhage in either arm; no significant difference in major bleeding — addressing the key safety concern that limited systemic fibrinolysis adoption after the original PEITHO trial
- Multinational, adequately sized for its primary composite (544 patients)
Limitations:
- Open-label treatment delivery
- Primary composite driven almost entirely by a softer endpoint (decompensation/collapse) rather than the harder death/recurrence components, which numerically favored control
- Industry (device manufacturer) sponsorship, funding, and manuscript-writing coordination
- Age-restricted population (18–80y) and specific severity-marker inclusion criteria limit generalizability to broader intermediate-risk PE
8. Interpretation & Practice Impact
- Clinical Implications: Supports considering ultrasound-facilitated catheter-directed fibrinolysis for carefully selected intermediate-risk PE patients (meeting the specific RV:LV/troponin/severity criteria used in this trial) to reduce acute deterioration, without the major-bleeding penalty seen with full-dose systemic fibrinolysis.
- Mechanistic Coherence: The low, localized thrombolytic dose plausibly explains preserved efficacy on hemodynamic decompensation without the systemic bleeding risk of full-dose IV fibrinolysis — consistent with the trial's design rationale.
- Systems-Level Takeaway: As with the original PEITHO experience, the honest interpretation should stay focused on the decompensation/collapse endpoint specifically, rather than over-extrapolating to a mortality or recurrence benefit, given the numerically worse (though statistically imprecise) death/recurrence point estimates.
9. Controversies & Subsequent Evidence
- Editorial Commentary: An accompanying NEJM editorial ("Advanced Therapy for Intermediate-Risk Pulmonary Embolism") and independent commentary have both noted that the primary composite is driven by a soft endpoint, and that the most clinically meaningful component (PE-related death) moved in the wrong direction (3 vs 1), warranting caution in over-interpreting the topline superiority result.
- Guideline Integration: Contributes directly to the 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults; represents the first randomized evidence directly supporting catheter-based intervention over anticoagulation alone in this population, contrasting with the original (systemic fibrinolysis) PEITHO trial's unfavorable bleeding profile.
10. Summary & Executive Takeaway
Summary: HI-PEITHO randomized 544 patients with intermediate-risk PE to ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation or anticoagulation alone. The primary composite (7-day PE-related death, decompensation/collapse, or recurrence) was significantly lower with the intervention (4.0% vs 10.3%, P=0.005), driven almost entirely by reduced cardiorespiratory decompensation/collapse (3.7% vs 10.3%). Major bleeding and mortality did not differ significantly; no intracranial hemorrhage occurred in either arm.
Overall Takeaway: In carefully selected intermediate-risk PE, ultrasound-facilitated catheter-directed fibrinolysis reduces acute hemodynamic deterioration without the major-bleeding penalty of systemic fibrinolysis — a meaningful advance, but one whose primary-composite benefit rests on a softer clinical endpoint, while the hardest endpoint (death) showed no benefit and numerically favored anticoagulation alone.
11. Bibliography
- Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism (PEITHO). N Engl J Med. 2014;370(15):1402-1411.
- Götzinger F, et al. Interventional therapies for pulmonary embolism. Nat Rev Cardiol. 2023;20:670-684.